The GORAB Knockout NCI-H1975 Polyclonal Cells consist of a polyclonal population of NCI-H1975 lung adenocarcinoma cells that have been subjected to CRISPR/Cas9-mediated gene disruption targeting GORAB. As a polyclonal knockout product, this model avoids single-cell clonal expansion and preserves a broader representation of genomic diversity, making it suitable for bulk-population studies where heterogeneous knockout effects are of interest. This loss-of-function model enables the investigation of GORAB-dependent processes in a cancer-relevant context. NCI-H1975 is a widely characterized human non-small cell lung cancer cell line established from the adenocarcinoma of a 63-year-old female.
It harbors an activating mutation in the epidermal growth factor receptor (EGFR L858R), leading to constitutive kinase activity and downstream signaling through RAS?CMAPK and PI3K?CAKT pathways. This cell line is extensively used in translational oncology to study EGFR-targeted therapy, acquired resistance mechanisms, and tumor progression. The epithelial origin and molecular features of NCI-H1975 provide a physiologically relevant platform for examining the interplay between oncogenic signaling and cellular trafficking pathways. GORAB is a member of the golgin family of coiled-coil proteins that reside at the cytoplasmic face of the Golgi apparatus.
It functions primarily in the organization of the trans-Golgi network and in the regulation of vesicular transport. GORAB operates downstream of the small GTPases RAB6A and RAB6B, interacting directly with the GARP (Golgi-associated retrograde protein) complex and COPI coatomer components to facilitate retrograde trafficking from endosomes to the Golgi. Additionally, GORAB is critical for proper protein glycosylation and for the efficient secretion of extracellular matrix proteins, particularly collagen type I and fibronectin. Through these activities, GORAB integrates Golgi morphology with extracellular matrix deposition, a process essential for tissue homeostasis and frequently dysregulated in cancer.
The use of GORAB knockout NCI-H1975 cells allows researchers to dissect how Golgi-mediated secretion influences the behavior of EGFR-mutant lung adenocarcinoma. Given that GORAB loss is associated with connective tissue disorders like geroderma osteodysplasticum, its depletion in a cancer model may uncover links between impaired matrix secretion and tumor invasiveness. In NSCLC, aberrant Golgi trafficking has been implicated in altered glycosylation of growth factor receptors and adhesion molecules, which can modulate cell migration, invasion, and drug sensitivity. This model thus serves as a valuable tool to study whether GORAB-dependent secretion pathways intersect with EGFR-driven oncogenic signaling to affect cancer cell phenotype.
Researchers can employ this knockout product in a range of assays. Immunofluorescence can assess Golgi morphology, while ELISA quantifies collagen I secretion. Glycosylation changes can be detected by lectin blotting. Functional assays include Transwell migration/invasion and wound healing. Western blotting monitors EGFR downstream targets like p-ERK and p-AKT, and viability assays evaluate drug sensitivity. The polyclonal format supports pooled screens and population-level studies. To obtain additional information or inquire about custom projects, please contact Ascent Research.
